<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Isavuconazole Effective in UncCAs and HMs</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-16</style></pages><abstract><style  face="normal" font="default" size="100%">Patients with invasive fungal disease and comorbid conditions such as hematologic malignancy and uncontrolled malignancy were successfully treated with the novel triazole antifungal agent isavuconazole, regardless of minimum inhibitory concentrations required by baseline Aspergillus spp isolates. This article presents data according to type of malignancy from the Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis trial [SECURE; NCT00412893].</style></abstract><number><style face="normal" font="default" size="100%">28</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>